Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer

NCT04024800 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple-negative Breast Cancer

Interventions

BIOLOGICAL: AE37 Peptide vaccine
BIOLOGICAL: Pembrolizumab

Sponsor

NuGenerex Immuno-Oncology

Collaborators

[object Object]
[object Object]